MAFPCAS# 188404-10-6 |
- Atrasentan
Catalog No.:BCC1379
CAS No.:173937-91-2
- sitaxsentan
Catalog No.:BCC1951
CAS No.:184036-34-8
- Zibotentan (ZD4054)
Catalog No.:BCC2524
CAS No.:186497-07-4
- Atrasentan hydrochloride
Catalog No.:BCC1380
CAS No.:195733-43-8
- Avosentan
Catalog No.:BCC1387
CAS No.:290815-26-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 188404-10-6 | SDF | Download SDF |
| PubChem ID | 10429254 | Appearance | Powder |
| Formula | C21H36FO2P | M.Wt | 370.49 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Methyl Acetate : ≥ 10 mg/mL (26.99 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | (5Z,8Z,11Z,14Z)-1-[fluoro(methoxy)phosphoryl]icosa-5,8,11,14-tetraene | ||
| SMILES | CCCCCC=CCC=CCC=CCC=CCCCCP(=O)(OC)F | ||
| Standard InChIKey | KWKZCGMJGHHOKJ-ZKWNWVNESA-N | ||
| Standard InChI | InChI=1S/C21H36FO2P/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-25(22,23)24-2/h7-8,10-11,13-14,16-17H,3-6,9,12,15,18-21H2,1-2H3/b8-7-,11-10-,14-13-,17-16- | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Potent, irreversible inhibitor of fatty acid amide hydrolase (FAAH, anandamide amidase), the enzyme responsible for anandamide hydrolysis (IC50 = 2.5 nM). Also binds irreversibly to CB1 receptors (IC50 = 20 nM). |
MAFP Dilution Calculator
MAFP Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.6991 mL | 13.4956 mL | 26.9913 mL | 53.9826 mL | 67.4782 mL |
| 5 mM | 0.5398 mL | 2.6991 mL | 5.3983 mL | 10.7965 mL | 13.4956 mL |
| 10 mM | 0.2699 mL | 1.3496 mL | 2.6991 mL | 5.3983 mL | 6.7478 mL |
| 50 mM | 0.054 mL | 0.2699 mL | 0.5398 mL | 1.0797 mL | 1.3496 mL |
| 100 mM | 0.027 mL | 0.135 mL | 0.2699 mL | 0.5398 mL | 0.6748 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Pellitorine
Catalog No.:BCN4043
CAS No.:18836-52-7
- Isodomoic acid G
Catalog No.:BCN1839
CAS No.:188346-81-8
- Massonianoside B
Catalog No.:BCN1164
CAS No.:188300-19-8
- Californidine
Catalog No.:BCC8137
CAS No.:18830-99-4
- 8alpha-(2-Methylacryloyloxy)hirsutinolide
Catalog No.:BCN7109
CAS No.:188293-70-1
- (±)-Propionylcarnitine chloride
Catalog No.:BCC6719
CAS No.:18828-58-5
- Methylproamine
Catalog No.:BCC1741
CAS No.:188247-01-0
- (±)-Octanoylcarnitine chloride
Catalog No.:BCC6715
CAS No.:18822-86-1
- H-Tyr(tBu)-OH
Catalog No.:BCC3129
CAS No.:18822-59-8
- H-Ser(tBu)-OH
Catalog No.:BCC3032
CAS No.:18822-58-7
- NocII
Catalog No.:BCC5704
CAS No.:188119-47-3
- AWD 131-138
Catalog No.:BCC4045
CAS No.:188116-07-6
- Paederosidic acid
Catalog No.:BCN3438
CAS No.:18842-98-3
- Scandoside
Catalog No.:BCN3449
CAS No.:18842-99-4
- SBI-0206965
Catalog No.:BCC3984
CAS No.:1884220-36-3
- TFM-4AS-1
Catalog No.:BCC6069
CAS No.:188589-61-9
- Cl-4AS-1
Catalog No.:BCC7780
CAS No.:188589-66-4
- GSK3787
Catalog No.:BCC2263
CAS No.:188591-46-0
- 3-hydroxymorindone
Catalog No.:BCN3126
CAS No.:80368-74-7
- 4,5-Di-O-caffeoylquinic acid methyl ester
Catalog No.:BCN6492
CAS No.:188742-80-5
- N-Acetylcaprolactam
Catalog No.:BCC9081
CAS No.:1888-91-1
- SC 560
Catalog No.:BCC7111
CAS No.:188817-13-2
- 8-Glucosyl-5,7-dihydroxy-2-(1-methylpropyl)chromone
Catalog No.:BCN7505
CAS No.:188818-27-1
- Streptozotocin
Catalog No.:BCN3834
CAS No.:18883-66-4
Inhibition of phospholipase A1, lipase and galactolipase activities of pancreatic lipase-related protein 2 by methyl arachidonyl fluorophosphonate (MAFP).[Pubmed:22835523]
Biochim Biophys Acta. 2012 Nov;1821(11):1379-85.
Methyl arachidonyl fluorophosphonate (MAFP) is a known inhibitor of cytosolic phospholipase A2 and some other serine enzymes. MAFP was found here to be an irreversible inhibitor of human pancreatic lipase-related protein 2 (HPLRP2), an enzyme displaying lipase, phospholipase A1 and galactolipase activities. In the presence of MAFP, mass spectrometry analysis of HPLRP2 revealed a mass increase of 351Da, suggesting a covalent binding of MAFP to the active site serine residue. When HPLRP2 was pre-incubated with MAFP before measuring residual activity, a direct inhibition of HPLRP2 occurred, confirming that HPLRP2 has an active site freely accessible to solvent and differs from most lipases in solution. HPLRP2 activities on tributyrin (TC4), phosphatidylcholine (PC) and monogalactosyl dioctanoylglycerol (C8-MGDG) were equally inhibited under these conditions. Bile salts were not required to trigger the inhibition, but they significantly increased the rate of HPLRP2 inhibition, probably because of MAFP micellar solubilization. Since HPLRP2 is active on various substrates that self-organize differently in the presence of water, HPLRP2 inhibition by MAFP was tested in the presence of these substrates after adding MAFP in the course of the lipolysis reaction. In this case, the rates of inhibition of lipase, phospholipase A1 and galactolipase activities were not equivalent (triglycerides>PC>MGDG), suggesting different enzyme/inhibitor partitioning between the aqueous phase and lipid aggregates. The inhibition by MAFP of a well identified phospholipase A1 (HPLRP2), present in pancreatic juice and also in human monocytes, indicates that MAFP cannot be used for discriminating phospholipase A2 from A1 activities at the cellular level.
[Dendritic cell vaccine modified by murine mAFP gene enhances immunoprotective effect on liver carcinogenesis and tumor development in mice].[Pubmed:18788625]
Zhonghua Zhong Liu Za Zhi. 2008 Apr;30(4):250-4.
OBJECTIVE: To construct a dendritic cell vaccine transduced by murine alpha-fetoprotein (MAFP) gene, and evaluate its immunoprotective effect on C57BL/6J mice during the induction of hepatocellular carcinoma by diethylnitrosamines, carbon tetrachloride and ethanol. METHODS: Dendritic cells (DCs) were induced and augmented by murine IL-4 and GM-CSF, and transfected by recombinant adenovirus engineered with MAFP gene. Major MHC class I and II, B7.1 (CD80), B7.2 (CD86), CD18a, and CD54 molecules on DC were analyzed by FACS. 80 C57BL/6J male mice were randomly divided into 4 groups (20 mice per group): Simple DC inoculated group, pAdBM5-MAFP-DC inoculated group, pAdBM5-MAFP plasmid inoculated group, and PBS control group. They were immunized once with 5 x 10(5) DCs (0.1 ml)/mouse administered s. c. in the left flank or 100 mg pAdBMS-MAFP plasmid/mouse administered i. m. in the left tibialis anterior muscle. Inoculation was conducted once a week for 4 weeks after 3 times consecutive immunization initially. At the same time of immunization, DEN/CCl4/ethanol were given to induce hepatocellular carcinoma. Tumor incidence was assessed after 20 weeks. RESULTS: A transgenic DC vaccine was successfully constructed and the MAFP transgenic DCs expressed high level molecules of major MHC class I and II , B7.1, B7.2, CD18a, and CD54. After the 20-week induction, the incidence of primary hepatocellular carcinoma (PLC) was 70.0% in simple DC inoculated group, 25.0% in pAdBMS-MAFP-DC inoculated group, 65.0% in pAdBM5-MAFP plasmid inoculated group, and 75.0% in PBS control group. There was a significant difference between group B and other groups (P < 0.05). CONCLUSION: MAFP transgenic DC tumor vaccine inoculation may induce strong immunoprotection against liver carcinogenesis and tumor development and reduce PLC incidence induced by DEN/CCl4/ethanol.
